← Leaderboards
Samir Khleif
Clinical Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseResponseManuscriptsVaccinesAntigensCancer VaccinesTumorImmune SystemHla-A2 AntigenPeptidesMalignant NeoplasmsClinical TrialsVascular Endothelial Growth Factor Receptor-2LeadGenerationsSolid NeoplasmPlayAngiogenesisImmunePublicationsSmall MoleculeTumor ImmunologyBinding (Molecular Function)Malignant Neoplasm Of Cervix Uteri
Grant awards (28)
Enhancing immune response strategies:$398,210
ZIA · FY2012 · CA · contact PI
Clinical trial development in cancer vaccines$199,105
ZIA · FY2012 · CA · contact PI
Anti-angiogenesis targeted vaccine therapy$66,369
ZIA · FY2012 · CA · contact PI
Enhancing immune response strategies:$741,549
ZIA · FY2011 · CA · contact PI
Clinical trial development in cancer vaccines$370,775
ZIA · FY2011 · CA · contact PI
Anti-angiogenesis targeted vaccine therapy$123,592
ZIA · FY2011 · CA · contact PI
Enhancing immune response strategies:$761,585
ZIA · FY2010 · CA · contact PI
Clinical trial development in cancer vaccines$415,410
ZIA · FY2010 · CA · contact PI
Anti-angiogenesis targeted vaccine therapy$138,470
ZIA · FY2010 · CA · contact PI
Development a combined prophylactic and therapeutic cervical cancer vaccine u$69,235
ZIA · FY2010 · CA · contact PI
Enhancing immune response strategies:$489,687
ZIA · FY2009 · CA · contact PI
Clinical trial development in cancer vaccines$367,265
ZIA · FY2009 · CA · contact PI
Anti-angiogenesis targeted vaccine therapy$244,843
ZIA · FY2009 · CA · contact PI
Development a combined prophylactic and therapeutic cervical cancer vaccine u$122,422
ZIA · FY2009 · CA · contact PI
Development a combined prophylactic and therapeutic cervical cancer vaccine u$290,219
Z01 · FY2008 · CA · contact PI
Enhancing immune response strategies:$290,219
Z01 · FY2008 · CA · contact PI
Anti-angiogenesis targeted vaccine therapy$193,479
Z01 · FY2008 · CA · contact PI
Clinical trial development in cancer vaccines$193,479
Z01 · FY2008 · CA · contact PI
Development a combined prophylactic and therapeutic cervical cancer vaccine u$398,219
Z01 · FY2007 · CA · contact PI
Clinical trial development in cancer vaccines$398,219
Z01 · FY2007 · CA · contact PI
Enhancing immune response strategies:$398,219
Z01 · FY2007 · CA · contact PI
Anti-angiogenesis targeted vaccine therapy$398,219
Z01 · FY2007 · CA · contact PI
Clinical trial development in cancer vaccines$0
Z01 · FY2006 · BC · contact PI
Development a combined prophylactic and therapeutic cerv$0
Z01 · FY2006 · BC · contact PI
Enhancing immune response strategies:$0
Z01 · FY2006 · BC · contact PI
Anti-angiogenesis targeted vaccine therapy$0
Z01 · FY2006 · BC · contact PI
Cancer Vaccine Development$0
Z01 · FY2002 · BC
A PHASE I/II STUDY OF A VACCINIA-HPV RECOMBINANT$0
Z01 · FY2000 · SC